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INTRODUCTION
Heart failure (HF) is characterised as a pathophysiological
condition, where due to abnormality of cardiac function, the
heart fails to pump and eject blood at a rate commensurate
with the requirements of the metabolising tissuses. Clinical
manifestations of HF include progressing fatigue and weak-
ness, exertional and/or rest dyspnea, pulmonary congestion,
hepatomegaly, and ankle swelling. All listed symptoms no-
tably affect quality of life. These patients have a markedly
increased risk of life-threatening arrhythmias and the cause
of death most frequently is HF progression and/or ventricu-
lar arrhythmias.
HF development can involve electrical dyssynchrony be-
tween right and left ventricle contractions. In an electrocar-
diogram (ECG) it is seen as interventricular conduction ab-
normalities, mostly as left bundle branch block (LBBB) or
right bundle branch block (RBBB). Electrical and mechani-
cal dyssynchrony results in a deterioration of contractile
function of the heart and dilatation of ventricles.
For patients with moderate and severe HF pharmacotherpy
is frequently ineffective, because it cannot prevent uncoor-
dinated contractions of ventricles. For more than ten years,
pharmacotherpy has been complemented with cardiac re-
synchronisation devices all over the world. Cardiac resyn-
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The aim of this study was to evaluate treatment of patients with moderate and severe heart failure
(HF) who were resistant to pharmacotherapy in Latvia and to assess the cardiac
resynchronisation therapy (CRT) by exploring the predisposing factors which provides CRT effi-
cacy. We accomplished prospective analysis of left ventricle ejection fraction (LVEF) and other
parameter changes 12 and 24 months after CRT device implantation, dividing the population into
two groups: responders — to whom LVEF improvement was 10% and non-responders where
 10% LVEF improvement was not achieved. The study included 50 chronic HF patients with pre-
served sinus rhythm, who underwent CRT device implantation in Latvia at the Pauls Stradiòð
Clinical University Hospital from June 2009 to March 2012. In the group of patients where 12 and
24 months after CRT device implantation LVEF improvement 10% was achieved, there were
statistically significantly more patients with left bundle branch block (LBBB) QRS morphology,
wider QRS complex, nonischemic genesis of HF, and normal systolic blood pressure. Patients
with LVEF improvement had more pronounced ventricular dyssynchrony measured by Echo be-
fore CRT device implantation and, accordingly, the CRT mode was programmed as left ventricle
paced before right ventricle and close to 100% biventricular pacing was achieved and the patient
was female.
Key words: cardiac resynchronisation therapy, heart failure.
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chronisation therapy (CRT) restores adequate coordination
between atria and ventricles, provides coordinated contrac-
tion of both ventricles and prevents cardiac dyssynchrony,
which is one of the main reasons for poor prognosis to HF
patients.
Selection of HF patients for CRT is based on three criteria
— HF functional class according to NYHA (New York
Heart Association), QRS complex duration (QRS 120 ms
on ECG) and Echo parameters — left ventricle ejection
fraction (LVEF ) < 35% and left ventricle end diastolic di-
ameter (EDD) > 55 mm. Approximately 25–30% of patients
with CRT do not reach the expected effect on HF symptom
reduction and preventing progression (McMurray et al.,
2012; Dickstein et al., 2008).
CRT has been used for HF patient treatment since 2002.
The first implantation of a CRT device in Latvia was per-
formed in 2006 (J. Ansabergs, N. Nesterovics, M. Blum-
bergs). Over the last years, the patient population with CRT
devices in Latvia has been rapidly growing, but the amount
of implanted devices is still not sufficient (Fig. 1). Compari-
son of data from Latvia with data from other European
countries shows that we are far from the leaders. On aver-
age in Eastern Europe there are 50–150 implantations per 1
million a year, compared to 150–220 CRT device implanta-
tions in Western Europe (Vardas et al., 2012; Arribas et al.,
2014). In Latvia there were 56 CRT device implantations
performed per 1 million population in 2016.
There have been no prospective or retrospective studies in
Latvia to analyse the efficacy of CRT. In randomised multi-
center trials the lack of CRT expected effectiveness is asso-
ciated with improper patient selection, suboptimal location
of left ventricle lead, inappropriate choise of medications as
well as with unwarranted CRT device programming.
The aim of this study was to evaluate the course of treat-
ment of patients with moderate and severe HF who are re-
sistant to pharmacotherapy in Latvia and to assess factors
that are related to CRT efficacy.
MATERIALS AND METHODS
The study included chronic HF patients with preserved si-
nus rhythm, who underwent CRT device implantation in
Latvia at Pauls Stradiòð Clinical University Hospital from
June 2009 to March 2012. During the study, evaluation of
treatment course of patients with moderate and severe HF
resistant to pharmacotherapy was accomplished by examin-
ing factors related to CRT efficacy. This clinical, longitudi-
nal, prospective study was approved by the Latvian Univer-
sity Research Institute of Cardiology clinical-physiological
research, drug and pharmaceutical clinical research Ethics
Committee.
CRT device implantations were performed according to the
European Society of Cardiology guidelines for HF therapy
(and updates), i.e. for patients with severe HF (NYHA func-
tional class III and ambulatory class IV HF) on optimal
pharmacological therapy (OPT), with QRS duration > 120
ms and LVEF < 35% and for patients with moderately se-
vere HF (NYHA functional class II) if patient is on OPT, is
in sinus rhythm, with LVEF  35% and QRS duration 150
ms.
All patients included in the study were in sinus rhythm and
for all patients, a CRT device with three leads was im-
planted — one lead located in the right atrium, one in the
right ventricle, and one through the CS was directed to the
left ventricle. Consequently, all patients were provided with
pacing, both for atrium and ventricles. A Chest X-ray after
CRT device implantation is shown in Figure 2.
All patients were on OPT for HF treatment, which included
fixed doses of angiotensin-converting enzyme inhibitors
(ACEI) or angiotensin receptor blockers (ARB), beta-
blockers (BB) and mineralocorticoid receptor antagonists
(MRA).
The criteria of exclusion were permanent atrial fibrillation
where restoration and preservation of sinus rhythm was im-
possible or sinus rhythm was not stable, radiofrequency
catheter ablation of the atrioventricular junction due to par-
oxysmal or persistent atrial fibrillation, death of the patient,
transplantation of the heart and application of a ventricular
assist device (VAD).
There were 50 patients included and the follow-up visits
were arranged 0, 3, 6, 12, and 24 months after CRT device
implantation. From the excluded patients one had under-
went radiofrequency catheter ablation of the atrioventricular
junction (3 months after the inclusion visit) and two patients
died during the study (5 and 16 months after the inclusion
visit).
A database was created using Microsoft Office Excel. The
records contained information about gender and age, the
date of the CRT device implantation, HF (NYHA) func-
tional class, 6-minute walking distance, hypertension and
smoking, diabetes, dyslipidemia and anemia, body mass in-
Fig. 1. Cardiac resynchronisation device implantations at Pauls Stradiòð
Clinical University Hospital from 2006 to 2016. CRT-D, cardiac
resynchronisation device with defibrilation function; CRT-P, cardiac
resynchronisation device without defibrilation function.
314 Proc. Latvian Acad. Sci., Section B, Vol. 72 (2018), No. 6.
dex (BMI), C reactive protein (CRP), glomerular filtration
rate (GFR), B-type Natriuretic Peptide (BNP), heart rate,
QRS morphology and duration, etiology of HF, location of
CS lead (based on X-ray analysis), Echo parameters
(EDD, ESD, LAVI, LVEF, MR and interventricular dys-
synchrony), pharmacological therapy, and presence of
supraventricular and ventricular arrhythmias, and atrio-
ventricular conduction.
The average values of parameters and measurements of the
study population before CRT implantation are summarised
in Tables 1 and 2. Statistical analysis was made using SPSS
(Statistical Package for the Social Sciences for Windows),
version 19.0. Generally accepted methods of descriptive sta-
tistics were used for characterisation of the population.
Quantitative variables were described using mean arithme-
tic and standard deviation (SD), but in cases when the distri-
bution of data did not complete criteria for normal distribu-
tion, the median and the quartiles were used. The
distribution of data was checked using the Kolmogorov–
Smirnov test. Due to the insufficient number of patients
(< 30) two independent groups were compared using the
Mann–Whitney U-test. In compliance with a generally ac-
cepted principle in medical statistics, the level of signifi-
cance was p < 0.05.
RESULTS
All patients underwent CRT device implantation and objec-
tive and subjective parameters were measured before and 3,
6, 12, and 24 months after the implantation. The population
was divided into two groups (A and B) according to pro-
spective evaluation of LVEF improvement measured by
Echo:
Fig. 2. Chest X-ray after CRT device implantation in anterior-posterior and
lateral projections (images from Pauls Stradiòð Clinical University Hospi-
tal database, CRT implantation was performed by MD Nikolajs
Òesteroviès).
T a b l e 1
AVERAGE VALUES OF PARAMETERS OF THE STUDY POPULA-
TION BEFORE CRT IMPLANTATION
Age, years 64.6 ± 9.4
Males, % 66.7% ( n = 32)
Body mass index, kg/m2 29.56 ± 5.0
Diabetes, % 18.8 % (n = 9)
GFR < 60 ml/min/1.73m2, % 47.9 (n = 23)
BNP, pg/ml 1274 ± 151.80
NYHA class III / IV, % 85.41 (n=41)
6-minute walking distance, m 344.65 ± 123.83
History of hypertension, % 62.5 (n = 30)
History of smoking, % 72.9 (n = 35)
Hemoglobin, g/dl 13.91 ± 1.51
Nonischemic genesis of cardiomyopathy, % 43.8 (n = 21)
Ischemic genesis of cardiomyopathy, % 56.3 (n = 27)
LBBB, % 77.1 (n = 37)
EDD, mm 69.35 ± 0.84
LVEF, % 32 ± 0.73
CRT, cardiac resynchronisation therapy; GFR, glomerular filtration rate;
BNP, B-type Natriuretic Peptide; NYHA, New York Heart Association;
LBBB, left bundle branch block; EDD, end diastolic diameter; LVEF, left
ventricle ejection fraction
T a b l e 2










BB, beta-blockers; ACEI/ARB, angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers
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Group A (responders) included patients showing improve-
ment of LVEF 10%, 12 and 24 months after CRT device
implantation;
Group B (non-responders) included patients showing im-
provement of LVEF 10%, 12 and 24 months after CRT de-
vice implantation.
Significant differences between group A and B patients
were tested for 53 parameters: age and gender of patients,
HF functional class, 6-minute walking distance, history of
hypertension, smoking and diabetes, renal function, haemo-
globin, CRP, dyslipidemia, BMI, BNP, heart rate, QRS du-
ration and morphology, Echo parameters (VV dyssyn-
chrony, EDD, ESD, LVEF, LAVI, MR grade), and etiology
of HF. According to group of medications used for HF
treatment the differences between both groups were summa-
rised and patient answers on questions about quality of life
were evaluated. CRT device programming data were used
to determine differences in atrioventricular conduction dis-
turbances between groups A and B. Assessment of the inci-
dence of paroxysmal supraventricular and ventricular ar-
rhythmias, presence of ventricular dyssynchrony and
percentage of ventricular pacing after CRT implantation
was carried out.
Statistically significant differences between groups A and B
were found for five of the tested parameters and very sig-
nificant differences were found for four parameters (p =
0.05–0.1), 12 months after CRT device implantation. Corre-
lation analysis confirmed that systolic blood pressure, QRS
morphology, type of myocardial injury, interventricular
(V-V) dyssynchrony, CRT device dyssynchrony mode were
associated with clinical benefit. However, strong differ-
ences after 12 months were found for history of smoking,
total cholesterol, QRS duration and etiology of HF, and it is
likely that these parameters were involved in improvement
in patients in groups A and B. The results are summarised
in Table 3.
Twenty-four months after CRT implantation, statistically
significant differences between group A and B were found
for eight parameters and strong differences were found for
four parameters. Correlation analysis confirmed that clinical
benefit is associated with systolic blood pressure, QRS mor-
phology, type of myocardial injury, HF etiology, myocar-
dial revascularisation, interventricular (VV) dyssynchrony,
total cholesterol, and CRT device dyssynchrony mode.
However, gender of patient, QRS duration, left ventricle
end systolic diameter (ESD) and statin therapy may be in-
volved in improvement. The results are summarised in Ta-
ble 4.
DISCUSSION
Pharmacotherapy is the main tool for treatment of HF, but
there are cases when the contractile function of the heart is
restricted and positive effect of the pharmacotherapy cannot
be reached. In cases where a contributing factor of HF is
electrical dyssynchrony of ventricles and pharmacotherapy
does not provide the effect which is expected, CRT can be
used as an additional option for treatment of HF. This is the
first study conducted in Latvia carried out to gain better un-
derstanding of the existing situation by estimating CRT effi-
cacy. The first implantation of a CRT device in Latvia was
performed in 2006 and the period of study (2009–2012) oc-
curred during a rising rate of implantations.
Generally, CRT devices are used for patients with preserved
sinus rhythm, but 25–35% of HF patients with electrical
dyssynchrony have a permanent form of atrial fibrillation
(Arribas et al., 2014). In contrast to patients in sinus
rhythm, this group of patients has atrioventricular dyssyn-
chrony, irregular and often rapid ventricular rate and the de-
velopment of cardiomyopathy may be associated with fast
ventricular rate instead of ventricular dyssynchrony; in ad-
dition these patients frequently have more adverse reac-
tions. Therefore, patients with CRT who are in sinus rhythm
cannot be compared to patients with CRT in atrial fibrilla-
tion. The condition in Latvia is similar: approximately 1/3
of CRT implantations are performed to patients in atrial fib-
rillation, to whom radiofrequency catheter ablation of the
atrioventricular junction is done to provide 100% biven-
tricular pacing and to avoid a fast ventricular rate. In this
study only patients in sinus rhythm were included, which
restricted the number of patients.
In the currently available literature, no precise definition of
positive response to CRT effect is given. For HF patients
with NYHA class II, a positive CRT effect often is pre-
dicted prolongation of life expectancy, while for HF pa-
tients with NYHA class III and IV, positive effects are re-
duction of severe HF symptoms, improvement of quality of
life, reduced hospitalisation rate and even a small clinical
improvement due to CR
In earlier studies the selected primary endpoints were set
mortality and hopitalisation due to HF decompensation.
Significant reduction of mortality was observed in COM-
PANION (Bristow et al., 2004) and CARE-HF (Cleland et
al., 2005) trials that included HF patients with NYHA class
III and IV. But the data from later trials like MADIT-CRT
(Zareba et al., 2011) and REVERSE (Daubert et al., 2009),
which included patients with mild and moderate HF and
where the effect of CRT with ICD function was compared
to ICD alone, showed that mortality was very low in both
groups. Therefore, mortality is not an applicable criteria for
CRT efficacy evaluation for all HF patients, because the
group of patients with mild and moderate HF cannot be
compared to the group of patients with clinically severe HF.
In this study, which was conducted in Latvia, the reduction
of mortality could not be estimated, because during the
two-year period there were only two deaths and 24 months
is not a sufficient time period to estimate mortality reduc-
tion. However, reduced hospitalisation was observed in both
groups of patients with implanted CRT.
The cardinal clinical symptom of HF is exertional dyspnea.
Accordingly, for assessment of CRT efficacy, the patient
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can evaluate reduction of exertional dyspnea and weakness.
Clinical trials have established that CRT reduces symptoms
only to patients with severe heart failure; furthermore, the
REVERSE (Daubert et al., 2009) trial confirmed that there
was no improvement of symptoms to NYHA I and II class
HF patients. Consequently, in estimation of isolated clinical
symptoms there are approximately 20–30% non-responders
among NYHA class III and IV HF patients, but among
T a b l e 3
SUMMARY OF THE PARAMETERS ANALYSED 12 MONTHS
AFTER CRT DEVICE IMPLANTATION
Parameters Group A
48.9% ( n = 23)
Group B
51.1% (n = 24)
p value




43.5 (n = 10)
56.5 (n = 13)
25 (n = 6)






13 (n = 3)
78.3 (n = 18)
8.7 (n = 2)
16 (n = 4)
60 (n = 14)




356.8 ± 119.6 333.4 ± 128.9 0.642
Systolic blood pressure,
mm Hg
131.1 ± 14.5 119.8 ± 15.8 0.015
History of hypertension, % 69.6 (n = 16) 56 (n = 14) 0.332
History of smoking, % 60.9 (n = 14) 84.0 (n = 21) 0.072
Diabetes, % 26.1 (n = 6) 12.0 (n = 3) 0.279
BMI, kg/m2 29.91 (±4.7) 29.24 (±5.3) 0.583
CRP, mg/l 4.13 (±5.5) 4.0 (±4.1) 0.722
Reduced GFR, % 39.1 (n = 9) 56.0 (n = 14) 0.243
BNP, pg/ml 1172.6 (±723.0) 1367(±1291.4) 0.869
Hemoglobin, g/l 13.84 ± 1.82 13.81 ± 1.35 0.439
Total cholesterol, mmol/l 5.03 ± 1.32 4.32 ± 1.4 0.055
Statin therapy, % 69.6 (n = 16) 76.0 (n = 19) 0.616




91.3 (n = 21)
8.7(n = 2)
64.0 (n = 16)
36.0 (n = 9)
0.025
QRS duration, ms 176.17 (±21.05) 163.44 (±22.54) 0.071
Etiology of heart failure:
ischemic, %
nonischemic, %
43.5 (n = 10)
56.5 (n = 13)
68 (n = 17)
32.0 (n = 8)
0.087
Myocardial injury:
scar of LV after
myocardial infarction, %
no scars or diffuse
hypokinesia, %
30.4 (n = 7)
69.6 (n = 16)
64.0 (n = 16)














100 (n = 23)
0.0 (n = 0)
88.0 (n = 23)



























65.2 (n = 15)
34.8 (n = 8)
36.0 (n = 9)
64.0 (n = 16)
0.043
CRP, C reactive protein; LV, left ventricle; LAVI, left atrial volume index
T a b l e 4
SUMMARY OF THE PARAMETERS ANALYSED 24 MONTHS
AFTER CRT DEVICE IMPLANTATION
Parameter Group A
56.25% (n = 27)
Group B
43.75% (n = 22)
p value




44.4 ( n = 12)
55.6 ( n = 15)
19.0 (n = 4)






11.1 (n = 3)
77.8 (n = 21)
11.1 (n = 3)
18.2 (n = 4)
59.1 (n = 13)




354.0 ± 113.1 332.0 ± 136.0 0.594
Systolic blood pressure,
mm Hg
131.8 ± 14.7 117.5 ±14.1 0.002
History of hypertension, % 66.7 (n = 18) 33.3 (n = 9) 0.584
History of smoking, % 63.0 (n = 17) 81.8 (n = 18) 0.146
Diabetes, % 22.2 (n = 6) 18.2 (n = 4) 1.00
BMI, kg/m2 29.6 (±5.2) 29.43 (±4.8) 0.950
CRP, mg/l 4.4 (±5.9) 5.0 (±7.6) 0.737
Reduced GFR, % 40.7 (n = 11) 54.5 (n = 12) 0.336
BNP, pg/ml 1249.0 (±151.2) 1293.2 (±153.2) 0.833
Hemoglobin, g/l 14.16 ± 1.76 13.68± 1.23 0.687
Total cholesterol, mmol/l 4.98(± 1.28) 4.16(±1.08) 0.020
Statin therapy, % 63.0 (n = 17) 86.4 (n = 19) 0.065




96.3 (n = 26)
3.7 (n = 1)
54.5 (n = 12)
45.5 (n = 10)
0.001
QRS duration, ms 175.15 (±20.29) 162.82(±23.25) 0.099
Etiology of heart failure:
ischemic, %
nonischemic, %
40.7 (n = 11)
59.3 (n = 16)
77.3 (n = 17)
22.7 (n = 5)
0.001
Myocardial injury:
scar of LV after myocardial
infarction, %
no scars or diffuse
hypokinesia, %
29.9 (n = 7)
74.1 (n = 20)






40.7 (n = 11)
59.3 (16)
76.2 (n = 16)
23.8 (5)
0.014




96.3 ( n = 26)
3.7 (n = 1)
90.9 (n = 20)
9.1 (n = 2)
0.859
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NYHA class I and II there would almost zero non-respond-
ers.
In multiple trials as the most significant criteria of CRT ef-
ficacy is considered to be changes of LVEF (Daubert et al.,
2009; Zareba et al., 2011; Yu et al., 2005). It has been es-
tablished that reduction of left ventricle volume and in-
crease of LVEF are correlated with reduction of clinical
symptoms and mortality in the CRT group. For patients
with 10% left ventricle end-systolic volume reduction after
CRT device implantation three-year survival reaches 90%
compared to 50% patients who do not achieve 10% left ven-
tricle end-systolic volume reduction (Yu et al., 2005).
In our study 48.9% patients achieved 10% of LVEF im-
provement in 12 months. But during the 24-month period,
the results were 56.25%. It can be assumed that only
slightly more than a half of the patients achieves Echo posi-
tive improvement of HF, but the study showed that the ef-
fect of CRT depends not only on LVEF and positive
remodelation of the left ventricle. Improvement of subjec-
tive symptoms, improvement of NYHA class, reduction of
hospitalisation rate and delay of development of arrhyth-
mias was also often achieved in the group of patients where
LVEF improvement was 5–10%.
A statistically significant difference between groups A and
B was found for systolic blood pressure (SBP). Correlation
analysis showed that change in SBP is associated with im-
provement in both groups. The study also confirmed that
SBP was lower in the group of non-responders. It can be
concluded that lowering SBP 120 mmHg is not recom-
mended, but this is hard to achieve because optimal phar-
macotherapy includes several antihypertensive medications
(ACEI/ ARB, BB, diuretics) and patients with severe HF al-
ready are hypotensive. Moreover, profound hypotension
may lead to hypoperfusion of organs and cause decrease of
CRT efficacy.
At the beginnig of the CRT “era”, one of the leading criteria
of CRT efficacy was considered to be QRS duration, but
currently, QRS morphology also is analysed as an efficacy
contributing factor.
In the largest CRT trial MADIT-CRT (n = 1820) where HF
patients in NYHA class I and II were included (Moss et al.,
2009; Zareba et al., 2011), reduction of mortality and hospi-
talisation in a CRT-D group was compared to an ICD
group. It was estimated that reduction of relative risk in the
CRT group was 34% (p < 0.001), compared to 57% (p <
0.001) in a subgroup that consisted of patients with LBBB.
In the more notable MADIT-CRT report, which determined
CRT long-term efficacy, seven-year data analysis of pa-
tients showed moderate clinical symptoms and significantly
reduced systolic function of the left vetricle (published in
2014). In the group with CRT and LBBB, mortality was
18% in comparison to 29% (p = 0.002) in the ICD group.
This suggests that nine patients should be treated with
CRT-D to save one life in a seven-year period (Goldenberg
et al., 2014).
In our study comparative analysis 24 months after CRT im-
plantation, LBBB was shown in 96.3% (n = 26) of group A
and 54.5% (n = 12) of group B patients. There was a moder-
ate correlation between improvement and QRS morphology
(rs = 0.498, p < 0.001) and in a longer the period there was
more pronounced improvement for patients with LBBB.
LBBB is determinative criteria for CRT efficacy. This could
be explained with more pronounced negative remodelation
of left ventricle in patients of this group causing greater im-
provement due to CRT, as shown in international studies
and in the present study. Studies also have established less
improvement of NYHA class for patients with RBBB (Le-
ong et al., 2012), which may be associated with inferior
CRT efficacy.
In most trials where etiological factors of HF are explored,
patients are divided into two large groups — a group of pa-
tients with ischemic genesis of HF to whom the underlying
cause of HF is CAD and a group of patients with non-
ischemic genesis of HF to whom cause of dilated cardio-
myopathy is not related to CAD. Clinical efficacy of CRT
in both groups was evaluated in a subanalysis of the MA-
DIT — CRT trial (Barsheshet et al., 2011; Zareba et al.,
2011). There were 1046 patients with ischemic cardiomyo-
pathy and 774 patients with nonischemic cardiomyopathy
included in analysis; the follow-up was 2.4 years. Patients
with ischemic cardiomyopathy achieved 34% (p < 0.001)
reduction of mortality and HF decompensation by compari-
son of a CRT — D group to an ICD group, but patients with
nonischemic cardiomyopathy achieved 44% (p < 0.002) re-
duction of mortality and HF decompensation in the CRT —
D group, compared to the ICD group.
In our study patients were also divided by etiological factor
of HF.
The percentage of patients with ischemic and nonischemic
cardiomyopathy in our study was 56.3% (n = 27) and 43.8%
(n = 21), respectively. Differences between groups A and B
were observed already after 12 months, but the most evident
differences were observed after 24 months, in group A
40.7% (n = 11) of patients and in group B 77.3% (n = 17) of
patients had ischemic cardiomyopathy, however, percentage
of nonischemic cardiomyopathy in group A and B was
59.3% (n = 16) and 22.7% (n = 5), respectively (p = 0.01).
Multicenter trials and also this study established that pa-
tients with nonischemic genesis of HF gain more benefit
from CRT when compared to patients with ischemic genesis
of HF. This can explained by the anatomical structure of the
left ventricle. After myocardial infarction hypokinetic and
akinetic scars are involved in the development of HF and
maintain the progression of HF, but in patients with
nonischemic genesis of HF ventricles are diffusely enlarged
and better comply with pacing and, therefore, even conduc-
tion of impulse can be provided.
Patients were divided into groups based on evaluation of
echocardiographic localisation of myocardial injury. One
group included patients with echocardiographically identi-
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fied scars in one of the walls of left ventricle and the second
group included patients to whom local scars were not found
or diffuse hypokinesia was identified, which usually indi-
cates nonischemic genesis of HF. Twenty-four months after
CRT implantation in group A 29.9% (n = 7) of patients had
myocardial scar and 74.1% (n = 20) had diffuse hypo-
kinesia. However, in group B 77.3% (n = 17) of patients
had localised injury of left ventricle and only 22.7% (n = 5)
of patients had diffuse hypokinesia (p < 0.001). This indi-
cates that patients with ischemic genesis of HF are less fa-
vourable candidates for high efficacy of CRT.
In our study we also analysed the revascularisation of myo-
cardium, if it was performed before CRT device implanta-
tion. In group A 24 months after CRT implantation 40.7%
(n = 11) of patients had underwent revascularisation, How-
ever, in group B there were 76.2% (n = 16) revascularised
patients (p = 0.014). This also confirms that patients with
ischemic genesis of cardiomyopathy are more likely to be
nonresponders.
CRT is an effective method of treatment for HF patients
with widened QRS complex. Studies and meta-analyses
show that patients with significantly widened QRS complex
gain the greatest benefit from CRT (Sipahi et al., 2011;
Stavrakis et al., 2012). In our study the analysis of QRS du-
ration before CRT implantation showed a statistically
strong difference (p = 0.099) between group A and B 24
months after implantation. A wider QRS complex before
CRT device implantation was associated with better effect
of CRT.
In most CRT studies females are in the minority (24% of
CRT candidates in European population); therefore, it may
be concluded that in the general population the proportion
of males with severe systolic dysfunction and wide QRS
complex is greater (Zabarovskaja et al., 2012; Yi-Zhou et
al., 2012). However, several studies that included patients
with moderate and severe HF, reduced LVEF and wide
QRS showed less improvement in mortality and hospitalisa-
tions after CRT implantation for males when compared to
females (Yi-Zhou et al., 2012). In our study of 50 patients,
17 were females and 33 were males. In group A 24 months
after CRT implantation, 55.6% (n = 15) of patients were
males and 44.4% (n = 12) were females (p = 0.064). Corre-
lation analysis showed a weak correlation between gender
and improvement, but statistical significance was not
achieved (rs = –0.267, p = 0.064) due to the small number of
patients. It is likely that a study with a greater number of pa-
tients would show that females are better candidates for
CRT.
In our study 56.2% of patients had ischemic genesis of HF;
therefore, one of the parameters evaluated was total choles-
terol (TC) levels. In group A, 24 months after CRT device
implantation, TC was 4.98 (±1.28) mmol/l, compared to
4.16 (±1.08) mol/l (rs = –0.335, p = 0.020) in group B. It
should be noted that the lower TC level in group B could be
explained by a greater proportion of patients with ischemic
genesis of HF, as patients with CAD were prescribed group
medications for correction of dyslipidemia more often.
In group A, 24 months after CRT device implantation,
63.0% (n = 17) of patients were using statins, compared to
86.4% (n = 19) (p = 0.065) in group B. The explanation of
such results could be similar to that given above.
It has been established that reduction of left ventricle vol-
ume and increase of LVEF is correlated with reduction of
clinical symptoms and mortality in patients with CRT
(Brignole et al., 2013). In our study, change of left ventricle
end-systolic diameter (ESD) and end-diastolic diameter
(EDD) were followed throughout the course of research.
The difference in left ventricle ESD between group A and B
24 months after CRT implantation was slightly below the
level of statistical significance (p = 0.064). However, after
24 months, a significant difference between group A and B
was observed in V-V dyssynchrony: 51.37 (±19.45) ms in
group A and 29.14 (±17.41) ms (p < 0.001) in group B.
There was a weak correlation (rs = –0.361, p = 0.013) be-
tween V-V dyssynchrony and improvement. Consequently,
the data showed that better the effect of CRT may be ex-
pected with more pronounced V-V dyssynchrony before the
CRT implantation.
Two groups with different dyssynchrony prevention modes
were analysed. The first group included patients to whom
left ventricle was paced before the right ventricle (LV
RV) and the second group included patients with other pos-
sible modes — synchronous pacing of both ventricles and
right ventricle pacing before left ventricle (BiVV& RV
LV). In both groups (A and B) a significant difference (p =
0.042) was observed in CRT dyssynchrony after 24 months
between LVRV group and combined BiVV& RV LV
group. Twenty-four months data analysis showed that in
group A there were more patients with LV RV pacing
mode (65.2% (n = 15) and 63.0% (n = 17), respectively).
Accordingly, patients with LBBB, where CRT mode is
LV RV, can be considered as better candidates for effec-
tive CRT if compared to BiVV& RV LV.
CONCLUSIONS
The study showed that better effect of CRT may be ex-
pected in HF patients who have LBBB QRS morphology,
wider QRS complex, nonischemic genesis of HF, normo-
systolic blood pressure, left ventricular lead positioned in
lateral or posterolateral CS vein, severe ventricular dyssyn-
chrony and CRT mode which provides left ventricle pacing
before right ventricle and near 100% biventricular pacing,
and for female patients.
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SIRDS RESINHRONIZÂCIJAS TERAPIJAS EFEKTIVITÂTI NOTEICOÐO FAKTORU IZVÇRTÇJUMS PACIENTU ÂRSTÇÐANÂ
AR MÇRENU UN SMAGU SIRDS MAZSPÇJU LATVIJAS POPULÂCIJÂ 12 UN 24 MÇNEÐU PÇTÎJUMÂ
Pçtîjuma mçríis bija analizçt ârstçðanas norisi hroniskas sirds mazspçjas (HSM) pacientiem Latvijâ ar vidçji smagu un smagu klînisko
gaitu, rezistenci pret farmakoterapiju, ar implantçtâm sirds resinhronizâcijas iekârtâm, pçtot predisponçjoðos faktorus sirds resinhronizâcijas
terapijas (cardiac resynchronisation therapy, CRT) efektivitâtes nodroðinâðanâ. Prospektîvi tika analizçti kreisâ kambara izsviedes frakcijas
(ejection fraction, EF) mçrîjumi un citi parametri 12 un 24 mçneðus pçc CRT ierîces implantâcijas, pacientus dalot grupâ, kur tika panâkta
10% EF uzlaboðanâs (responderi) un grupâ, kur netika panâkta 10% EF uzlaboðanâs (neresponderi). Pçtîjumâ analizçti 50 hroniskas sirds
mazspçjas pacienti ar saglabâtu sinusa ritmu, kuriem veikta CRT implantâcija Latvijâ, Paula Stradiòa Klîniskajâ universitâtes slimnîcâ, laika
posmâ no 2009. gada jûnija lîdz 2012. gada martam. Divpadsmit un 24 mçneðus pçc CRT ierîces implantâcijas, pacientu grupâ, kur tika
panâkta Eho KG 10% EF uzlaboðanâs, bija statistiski ticami vairâk pacientu ar Hisa kûlîða kreisâ zara pilnas blokâdes morfoloìiju, platâku
QRS kompleksu, neiðçmiskas ìençzes sirds mazspçju, normosistolisku asinsspiedienu. Pacientiem ar EF uzlaboðanos bija izteiktâka
kambaru disinhronija Eho KG mçrîjumos pirms CRT implantâcijas, attiecîgi CRT ierîcç tika ieprogrammçti kambaru disinhroniju
likvidçjoðie parametri, lai kreisais kambaris tiek stimulçts pirms labâ kambara, tika nodroðinâta tuvu 100% biventrikulâra stimulâcija, un
pacients bija sieviete.
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